LIXTE Biotechnology Holdings, Inc. announced the enrollment of the first patient in the Phase 1b portion of the Phase 1b/2 protocol (NCT05809830) to determine the appropriate dose of LB-100 given with a standard dose of doxorubicin. Once the dose is determined, a randomized Phase 2 study will be initiated seeking to gain evidence that the inclusion of doxorubicin increases time to a progression and/or overall survival of patients with advanced soft tissue sarcomas (ASTS).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.485 USD | +0.61% | -1.39% | +5.74% |
1st Jan change | Capi. | |
---|---|---|
+5.74% | 5.59M | |
+35.14% | 51.51B | |
-7.43% | 39.03B | |
+34.10% | 38.91B | |
-10.62% | 26.68B | |
+11.63% | 26.13B | |
-17.77% | 19.91B | |
+40.52% | 13.71B | |
+30.70% | 12.38B | |
-3.41% | 11.74B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- LIXTE Biotechnology Holdings, Inc. Announces the Enrollment of the First Patient in the Phase 1b Portion of the Phase 1b/2 Protocol